" class="no-js "lang="en-US"> Zhongchao Announces Drug Distributorship in China for Natco
Saturday, February 04, 2023

Zhongchao Announces Drug Distributorship in China of Indian Generic Drugs of Natco Pharma

Zhongchao, a platform-based internet technology company offering services to patients with oncology and other major diseases, has announced that Chongqing Xinjiang Pharmaceutical, one of the Chinese operating entities of which the Company consolidates the financial results with through certain contractual arrangements, will act as the drug distribution agent of certain drugs produced by Natco Pharma within Mainland China pursuant to certain agreements. Natco is a vertically integrated and R&D focused pharmaceutical company in India.

Through this cooperation, Xinjiang Pharmaceutical will introduce different products from Natco based on the needs of patients in China, for example, anti-influenza drugs during the flu season, and high demand anti-tumor and anti-rare diseases products. Both parties will work together to apply registration certificate of imported drugs and submit filings of sales agent, and will fully leverage their advantages and resources to effectively shorten the clinical trial approval and other processes and accelerate the progress of introducing quality drugs to the patients in China.

Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, “We are thrilled to announce the cooperation with Natco. While we continuously focus on strengthening our service model of Medical-Pharmaceutical-Patient in the field of oncology and other major diseases, we consider it an important step to introduce quality pharmaceutical products to the end market of China to benefit the patients.”

Mr. Yang further adds, “Due to compulsory licensing requirement in India, Indian generic drugs have the characteristics of early market penetration and good efficacy. Going forward, Xinjiang Pharmaceutical will continue to expand its drug import and export trade business, and introduce imported drugs based on the demands of Chinese patients and increase drug supply offerings. We have been committed to improving the drug accessibility and affordability for patients but bring in greater social economic benefits.”

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more